Breast conserving surgery for multifocal XXXX .

@entity1 @entity5 @entity0 @entity1722
OBJECTIVE: The purpose of this study is to examine the oncological safety of breast conserving surgery (BCS) for @entity1 with multifocal @entity0 . SUMMARY BACKGROUND DATA: Few studies have reported about BCS for multifocal @entity0 . BCS for multifocal @entity5 has a risk of local failure in previous reports, whereas recent studies reported the feasibility of BCS. However, because all studies have dealt with a small number of @entity1 , multifocal @entity0 is still considered a relative contraindication for BCS. METHODS: This retrospective study includes 478 @entity1 with multifocal @entity0 who underwent BCS or mastectomy and 930 with unifocal @entity5 who underwent BCS for stage 0-II. @entity5 was defined as 2 or more distinct @entity5 in the same quadrant. Of 478 @entity1 , 147 underwent BCS and 331 underwent mastectomy. We compared the local recurrence rate (LRR), disease free survival, and overall survival for BCS with mastectomy for multifocal @entity5 . In addition, the LRR of BCS for multifocal @entity5 was compared for unifocal @entity5 . RESULTS: There is no significant difference in stage distribution and other clinical and pathologic characteristics except @entity1722 for stage IIA between BCS and mastectomy for multifocal @entity5 . The mean follow-up period was 59.33 months (range, 1.00-177.20) for breast conserving group and 64.98 months (range, 6.23-196.03) for mastectomy group. The 5-year overall survival was 93.38% for BCS and 94.53% for mastectomy (log rank P = 0.208). The 5-year disease-free survival was 89.08% for BCS and 91.88% for mastectomy (log rank P = 0.451). The local failure occurred in 3 (2.0%) of 147 @entity1 underwent BCS, 3 (0.9%) of 331 @entity1 underwent mastectomy (P = 0.378). Compared with BCS for unifocal @entity5 @entity1 , the LRR of @entity1 with multifocal @entity5 was not statistically different (2.0% for multifocal, 1.3% for unifocal; P = 0.445). CONCLUSIONS: Our study demonstrates that BCS for multifocal @entity0 is oncologically safe in selected @entity1 .
